Evaluation of pregabalin-induced adverse events related to falls using the FDA adverse event reporting system and Japanese Adverse Drug Event Report databases.
Ririka MukaiShiori HasegawaRyogo UmetsuSatoshi NakaoKazuyo ShimadaHiroaki UranishiMayuko MasutaHonami SuzukiYuri NishibataMitsuhiro NakamuraPublished in: Journal of clinical pharmacy and therapeutics (2018)
This study is the first to evaluate the relationship between pregabalin and AEFs using the SRS analysis strategy. The risk of AEFs in the ≥60 years age group might increase compared to that in the <60 years age group. AEFs occurred almost within 1 week after pregabalin administration, and the median for AEF onset was 2 days. Our results show that patients should be closely monitored for AEFs for 1 week from the start of pregabalin administration.
Keyphrases
- adverse drug
- neuropathic pain
- postoperative pain
- end stage renal disease
- drug induced
- ejection fraction
- newly diagnosed
- chronic kidney disease
- electronic health record
- spinal cord
- spinal cord injury
- prognostic factors
- peritoneal dialysis
- high glucose
- patient reported outcomes
- machine learning
- oxidative stress
- big data
- diabetic rats
- study protocol
- patient reported